Latest stories on AGIO
Agios Pharmaceuticals Q2 2026 Earnings Preview
Seeking Alpha56 · neutralearnings
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data
Investing.com Analyst Ratings38 · neutralanalyst
Agios pares loss after abandoning sickle cell asset tebapivat
Seeking Alpha38 · neutralproduct/pr
Why Is AGIO Stock Falling Today?
Stocktwits News18 · bearishproduct/pr
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
Yahoo Finance32 · bearishgeneral
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)
InvestorsHub34 · bearishearnings
Agios Pharmaceuticals stock falls on trial update
Investing.com Markets34 · bearishgeneral
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease | AGIO Stock News
StockTitan63 · neutralproduct/pr
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
The Motley Fool73 · bullishproduct/pr
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
The Motley Fool67 · bullishproduct/pr
AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism
Stocktwits News67 · bullishproduct/pr
FDA Grants Priority Review to Agios’ Mitapivat—First Oral PK Activator Advances in Sickle Cell Disease
MarketChameleon73 · bullishproduct/pr
Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Treatment
Morningstar67 · bullishgeneral
Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone
Investors.com67 · bullishgeneral
Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Disease Treatment
Morningstar67 · bullishproduct/pr
Agios gains FDA priority review for Pyrukynd label expansion
Seeking Alpha73 · bullishproduct/pr
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease | AGIO Stock News
StockTitan73 · bullishproduct/pr
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
TipRanks24 · bearishgeneral
AGIOS PHARMACEUTICALS, INC. (AGIO) files 8-K
SEC 8-K50 · neutralgeneral
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event - Slideshow
Seeking Alpha55 · neutralproduct/pr
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript
Seeking Alpha63 · neutralproduct/pr
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Seeking Alpha63 · neutralproduct/pr